A 4-gene signature (ATM, RB1, FANCC, ERCC2) correlates with tumor absence post-neoadjuvant chemotherapy in muscle-invasive bladder cancer. The biomarker is more effective at predicting disease ...

Neal Shore, MD, FACS, emphasizes the significance of the VISION and TheraP trials in supporting the FDA approval of Lutetium-177 for patients with mCRPC who have undergone androgen receptor inhibitor ...

UTUC is a rare malignancy, primarily affecting older men, with smoking as a significant risk factor. Nephron-sparing approaches are gaining interest due to complications from nephroureterectomy and ...

Aquablation offers personalized treatment plans using real-time ultrasound and AI, distinguishing it from traditional TURP procedures. The heat-free nature of Aquablation reduces post-operative ...

SBRT shows promise in achieving progression-free survival in metastatic RCC without systemic therapy, despite limited high-level data. The absence of phase 3 trials leaves a gap in comparing SBRT ...

F-flotufolastat shows a 69% detection rate for recurrent prostate cancer in patients with PSA levels above 0.2 ng/mL post-prostatectomy. The agent demonstrates a 50% detection rate for PSAs below 0.2 ...

SunRISe-4 targets MIBC patients ineligible for or refusing cisplatin-based chemotherapy, addressing an unmet medical need. The trial evaluates TAR-200 plus cetrelimab and cetrelimab monotherapy, ...

Steerable suction catheters and scopes are revolutionizing stone disease surgery, enhancing safety and efficiency. The MONARCH trial and CVAC scope are key innovations in stone removal, allowing ...

Talazoparib plus enzalutamide significantly improved overall survival in mCRPC patients, including those with HRR gene mutations. The treatment's safety profile aligns with known data for talazoparib ...

Prostate cancer patients have a higher depression incidence (10%-40%) than the general population (9%). Racial disparities exist in depression diagnosis and treatment ...

PD-1/PD-L1 pathways are pivotal in cancer immunotherapy, enabling tumor immune evasion by inactivating T-cells through receptor-ligand interactions. Investigational agents in BCG-naive and ...

"We remain on track for the opening of phase 2 in the next few months. We also expect to see the full phase 1 results presented at a scientific meeting in 2025," says David E. Gauden, DPhil. Lutetium ...